Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Stage IV Prostate Cancer Clinical Trial

Official title:

A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02159950
• Other study ID #: I 250813
• Secondary ID: NCI-2014-01184I
• Status: Completed
• Phase: Phase 2
• Start date: January 2015

Study information

• Verified date: April 2023
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Tasquinimod may stop the growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether sipuleucel-T is more effective with or without tasquinimod in treating prostate cancer.

Description:

PRIMARY OBJECTIVES: I. To determine whether tasquinimod augments immune response to sipuleucel-T. SECONDARY OBJECTIVES: I. To assess the safety and tolerability of the combination of sipuleucel-T and tasquinimod in patients with castration-resistant metastatic prostate cancer. II. To obtain preliminary evidence of the clinical benefit of the combination of sipuleucel-T and tasquinimod; to include changes in prostate specific antigen (PSA) over time, and duration of progression-free survival/overall survival. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive sipuleucel-T intravenously (IV) over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive tasquinimod orally (PO) once daily (QD) beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression. After completion of study treatment, patients are followed up every 3 months for up to 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Metastatic asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC) patients who are eligible for sipuleucel-T
• Disease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility) and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
• Life expectancy >= 6 months
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Hemoglobin >= 100 g/L (>= 10 g/dL)
• Leukocytes >= 3,000/mm^3
• Absolute neutrophil count >= 1,500/mm^3
• Platelets >= 100,000/mm^3
• Total bilirubin =< 1.5 x laboratory upper limit of normal
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x laboratory upper limit of normal
• Creatinine =< 1.5 x laboratory upper limit of normal or calculated creatinine clearance of >= 50 mL/min (please use institutional formula)
• Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
• Urine protein < 1+; if >= 1+, 24 hour urine protein should be obtained and should be < 1000 mg
• Central nervous system (CNS): no recent history (within 6 month) of cerebrovascular accident, transient ischemic attacks, central nervous system or brain metastases
• Ability to understand and the willingness to sign a written informed consent document
• Patient verbalizes the ability to swallow and retain oral medication
• Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

• Patients who have received systemic steroids within 4 weeks prior to starting study treatment
• Patients who have received prior immunotherapies
• History of therapy for an autoimmune disorder
• Patients receiving any other investigational agents
• Any medical condition that would preclude adequate evaluation of the safety and toxicity of the study combination
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Association class II, III, or IV), angina pectoris requiring nitrate therapy, recent myocardial infarction (less than the last 6 months), cardiac arrhythmia, history of cerebrovascular accident (CVA) within 6 months; no uncontrolled hypertension (defined as blood pressure of > 160/90 mmHg) on medication or, history of peripheral vascular disease
• Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4
• History of psychiatric illness or social situations that would limit compliance with study requirements
• History of pancreatitis
• Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
• Systemic exposure to ketoconazole or other strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) isoenzyme inhibitors or inducers within 14 days prior to the start of study treatment; systemic exposure to aminodarone is not allowed within 1 year prior to the start of study treatment
• Ongoing treatment with sensitive cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) substrate or CYP1A2 substrate with narrow therapeutic range at the start of study treatment
• Ongoing treatment with CYP3A4 substrate with narrow therapeutic range at the start of study treatment
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of therapy
• Unwilling or unable to follow protocol requirements
• Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study drug

Related Conditions & MeSH terms

• Carcinoma
• Hormone-Resistant Prostate Cancer
• Metastatic Prostate Carcinoma
• Prostatic Neoplasms
• Recurrent Prostate Carcinoma
• Stage IV Prostate Cancer

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies

Biological:
• Sipuleucel-T
Given IV

Drug:
• Tasquinimod
Given PO

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (2)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute	Active Biotech AB

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Effects of Tasquinimod on the Inhibition of Immune Cells		Up to week 50
Primary	Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024		Baseline up to 50 weeks
Secondary	Change in PSA Response	PSA doubling time, PSA slope	Baseline to up to 3 years
Secondary	Duration of PSA Response		Up to 3 years
Secondary	Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4	The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.	Up to 3 years
Secondary	Immune Response		Week 6
Secondary	Immune Response		Week 10
Secondary	Immune Response		Week 26
Secondary	Immune Response		Week 50
Secondary	Immune Response (Arm 2 Only)		Week 0
Secondary	Objective Response Rates (Partial or Complete)		Up to 3 years
Secondary	Overall Survival		Up to 3 years
Secondary	Progression-free Survival		Up to 3 years
Secondary	Time to PSA Progression		Up to 3 years